Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis

One stock posted a large, data-driven gain in a week of little market reaction to clinical readouts, with Abivax’s first-in-class miRNA therapy demonstrating efficacy in ulcerative colitis.

Shares of Abivax S.A. (Euronext:ABVX; NASDAQ:ABVX) rose 586% on NASDAQ on Wednesday, for a market cap gain of about $3.7 billion, after the biotech reported miR-124 enhancer obefazimod led to a pooled clinical remission rate of 16.4% (p<0.0001) across two Phase III studies after an 8-week induction phase...